EI

262.9

-1.42%↓

SAN

85.88

-0.62%↓

MRK1

108.55

+0.56%↑

SHL.DE

47.18

-0.63%↓

ARGX

601.2

-1.25%↓

EI

262.9

-1.42%↓

SAN

85.88

-0.62%↓

MRK1

108.55

+0.56%↑

SHL.DE

47.18

-0.63%↓

ARGX

601.2

-1.25%↓

EI

262.9

-1.42%↓

SAN

85.88

-0.62%↓

MRK1

108.55

+0.56%↑

SHL.DE

47.18

-0.63%↓

ARGX

601.2

-1.25%↓

EI

262.9

-1.42%↓

SAN

85.88

-0.62%↓

MRK1

108.55

+0.56%↑

SHL.DE

47.18

-0.63%↓

ARGX

601.2

-1.25%↓

EI

262.9

-1.42%↓

SAN

85.88

-0.62%↓

MRK1

108.55

+0.56%↑

SHL.DE

47.18

-0.63%↓

ARGX

601.2

-1.25%↓

Search

UCB SA

Open

BrancheGesundheitswesen

199.05 -1.46

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

198.45

Max

202.4

Schlüsselkennzahlen

By Trading Economics

Einkommen

857M

Verkäufe

3.4B

KGV

Branchendurchschnitt

29.258

35.724

Dividendenrendite

0.7

Gewinnspanne

25.498

Angestellte

8,600

EBITDA

1.3B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+19.23% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.70%

3.09%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

2.8B

39B

Vorheriger Eröffnungskurs

200.51

Vorheriger Schlusskurs

199.05

Nachrichtenstimmung

By Acuity

50%

50%

172 / 372 Ranking in Healthcare

UCB SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

28. Juli 2025, 10:51 UTC

Market Talk

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

Peer-Vergleich

Kursveränderung

UCB SA Prognose

Kursziel

By TipRanks

19.23% Vorteil

12-Monats-Prognose

Durchschnitt 94.86 EUR  19.23%

Hoch 125 EUR

Tief 74 EUR

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für UCB SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

7 ratings

4

Buy

1

Halten

2

Sell

Stimmung

By Acuity

172 / 372 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.